Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2017

Collaborative Arrangement with Ipsen [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three months ended March 31, 2017 and 2016, collaboration revenues under the Ipsen Collaboration Agreement were as follows (in thousands):



	Three Months Ended March 31,
	2017			2016
Amortization of upfront payments and deferred milestone	$	4,305		$	1,198
Royalty revenue	224			—
Development cost reimbursements	337			—
Product supply agreement revenue	991			—
Cost of supplied product	(991		)	—
Royalty payable to GlaxoSmithKline on net sales by Ipsen	(336		)	—
Collaboration revenues under the Ipsen Collaboration Agreement	$	4,530		$	1,198

Collaborative Arrangement with Genentech [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three months ended March 31, 2017 and 2016, ex-U.S. royalty revenues and U.S. losses under the collaboration agreement with Genentech were as follows (in thousands):



	Three Months Ended March 31,
	2017			2016
Royalty revenues on ex-U.S. sales of COTELLIC included in Collaboration revenues	$	2,298		$	130
U.S. losses included in Selling, general and administrative expenses	$	(626	)	$	(7,293	)

Collaborative Arrangement with Takeda [Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

Schedule of Collaborative Revenues Under Collaboration Agreement

During the three months ended March 31, 2017, collaboration revenues under the Takeda Collaboration Agreement were as follows (in thousands):



	Three Months Ended March 31, 2017
Amortization of upfront payment	$	1,887
Development cost reimbursements	795
Collaboration revenues under the Takeda Collaboration Agreement	$	2,682